ImmunoTargets and Therapy

CombImmunoTherapy: Personalizing Oncology Treatment

ImmunoTargets and Therapy is pleased to announce a new Article Collection dedicated to examining CombImmunoTherapy (CIT) as a game-changing oncology treatment strategy.

This Collection, edited by the Editor-In-Chief Prof. Michael R. Shurin, is part of the new Game Changer series of Article Collections, focusing on breakthrough therapies, drugs, and technologies that have significantly altered the standard of care, leading to game-changing improvements in patient outcomes.

In 2011, the first immunotherapy for cancer was approved. Since then, the FDA has approved at least 11 immune checkpoint inhibitors and other types of immunotherapies, including CAR T-cell therapies. Currently, there are more than 1,000 immunotherapy clinical trials underway across the United States alone, with 15-20% of patients experiencing robust results. While immunotherapy has significant promise, traditional methods of cancer treatment, such as chemotherapy and radiation therapy, still prevail as the first line of treatment. As we learn more about factors such as the tumor microenvironment that influence treatment efficacy, one thing remains clear – there is a great need for personalized combination therapy. CIT provides a more tailored approach, allowing oncologists flexibility to effectively treat each individual patient.

While this call is open to receive manuscripts highlighting all aspects of CIT, the Editors are particularly interested in manuscripts relating to the following areas:

• Preclinical models investigating combinatorial immunotherapy strategies
• Promising combinatorial approaches currently in trial
• Interaction, safety, and contraindication data
• Current therapeutic drugs/antibodies in the pipeline
• Mechanistic action, targets, and immune effects of CIT
• Immunotherapy in combination with traditional chemotherapy and/or radiation therapy
• Cancer vaccines for CIT
• Combinational immunotherapy of patients with cancer and comorbid immune-mediated diseases

Submitting authors are eligible for a 20% discount on the Article Publishing charge by applying the following code at the point of submission: 0A8F9. If you have any queries regarding the Article Collection or would like to discuss a submission, please email the Commissioning Editor, Ashley Ambros.

Papers published within the Game Changer series will benefit from additional promotional activities across Taylor and Francis, increasing the discoverability and visibility of your research.

All manuscripts submitted to this Article Collection will undergo desk assessment and a full peer review. Please review the journal scope and author submission instructions prior to submitting a manuscript as it will be rejected if it does not fall within the scope of the journal.

The deadline for submitting manuscripts is 1^st of June 2026.

Keywords: Combination Immunotherapy; Cancer Vaccines; Cellular Immunotherapy; Immune Checkpoint Inhibitors; Personalized Medicine